3D eye imaging enters neurology offices

Article

Heidelberg Engineering is introducing SPECTRALIS, then office-based imaging device for tracking and measuring axonal change, at the 2010 meeting of the American Academy of Neurology in Toronto.

Heidelberg Engineering is introducing SPECTRALIS, then office-based imaging device for tracking and measuring axonal change, at the 2010 meeting of the American Academy of Neurology in Toronto. The SPECTRALIS Tracking Laser Tomographer uses its on-board Nsite Axonal Analytics to track and measure axonal changes within the retinal nerve fiber layer (RNFL) by capturing high resolution cross-sectional images of the eye.

Numerous peer-reviewed clinical studies have been published in the last several years investigating the relationship between RNFL and neurodegenerative diseases, especially multiple sclerosis. Patients with multiple sclerosis have been shown to have a thinner RNFL than healthy patients, and this is true for patients with and without prior episodes of optic neuritis.1 In addition, RNFL thickness has been shown to correlate with symptoms measured in physical disability scores such as the Expanded Disability Status Scale (EDSS). 1

“Even though SPECTRALIS offers one hundred times higher resolution than an MRI, we don’t expect our instrument to replace the role of MRI for neurologists,” noted Dr Kester Nahen, vice president of global marketing and business development at Heidelberg Engineering, “but we do believe that having an office-based instrument which can measure unmyelinated nerve loss in a fast and easy way will be a valuable asset for helping to evaluate patients with neurodegenerative conditions.”

References .Fisher J et al.,Ophthalmology Feb(13):324-332 (2007).

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.